Teleflex has acquired the Vascular Intervention division of BIOTRONIK, excluding IMDS products, effective July 1, 2025, to enhance its portfolio in the vascular medical device market.

Information on the Target

Teleflex has acquired almost the entire Vascular Intervention segment of BIOTRONIK, excluding the IMDS products. This acquisition, effective July 1, 2025, allows Teleflex to expand its portfolio in the vascular medical device sector. The Vascular Intervention line focuses on innovative solutions for the treatment of vascular diseases, positioning Teleflex for enhanced growth and operational diversification in this critical market.

With this acquisition, Teleflex aims to integrate cutting-edge technologies developed by BIOTRONIK into its existing offerings. This move reinforces Teleflex's commitment to delivering advanced healthcare solutions and expands its capabilities in vascular treatments, enabling the company to better serve healthcare providers and patients worldwide.

Industry Overview in the Target’s Specific Country

The vascular intervention market is witnessing substantial growth driven by the increasing prevalence of cardiovascular diseases and a growing aging population. In Germany, where BIOTRONIK is based, the healt